Literature DB >> 10217324

Effects of fosfomycin and imipenem-cilastatin on the nephrotoxicity of vancomycin and cisplatin in rats.

T Nakamura1, T Kokuryo, Y Hashimoto, K I Inui.   

Abstract

The nephrotoxicity of vancomycin and cisplatin and the protective effects of fosfomycin and imipenem-cilastatin on renal function have been studied in rats. The renal clearance of vancomycin after the induction of renal dysfunction was also evaluated by calculating the glomerular filtration rate (GFR) and its secretory clearance. Plasma concentrations of creatinine and urea nitrogen increased dose-dependently after vancomycin injection. No such increases were observed after co-treatment with fosfomycin or imipenem-cilastatin. Changes of N-acetyl-beta-D-glucosaminidase activity in the urine of vancomycin-treated rats were not remarkable compared with those in cisplatin-treated animals. The reduced renal clearance of vancomycin in rats with acute renal failure induced by vancomycin was because of a decrease in both GFR and secretory clearance. However, the changes in GFR and secretory clearance were not proportional-the change in GFR was more pronounced than that of secretory clearance in the experimental groups. In addition, the renal clearance of vancomycin was maintained at the control level after co-administration of fosfomycin or imipenem-cilastatin with vancomycin. These results suggest that vancomycin impairs glomerular filtration more markedly than renal tubular function as compared with cisplatin. Co-administration with fosfomycin or imipenem-cilastatin confers significant protection against the nephrotoxic effects of vancomycin.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10217324     DOI: 10.1211/0022357991772187

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  7 in total

1.  Effects of arbekacin and vancomycin on release of lactate dehydrogenase and fragmentation of DNA in LLC-PK1 kidney epithelial cells.

Authors:  T Nakamura; T Kokuryo; M Okuda; Y Hashimoto; K Inui
Journal:  Pharm Res       Date:  1999-07       Impact factor: 4.200

2.  In vitro activity of fosfomycin in combination with colistin against clinical isolates of carbapenem-resistant Pseudomas aeruginosa.

Authors:  Xiuzhen Di; Rui Wang; Bin Liu; Xin Zhang; Wentao Ni; Jin Wang; Beibei Liang; Yun Cai; Youning Liu
Journal:  J Antibiot (Tokyo)       Date:  2015-03-25       Impact factor: 2.649

3.  Pharmacodynamics of colistin and fosfomycin: a 'treasure trove' combination combats KPC-producing Klebsiella pneumoniae.

Authors:  Miao Zhao; Zackery P Bulman; Justin R Lenhard; Michael J Satlin; Barry N Kreiswirth; Thomas J Walsh; Amanda Marrocco; Phillip J Bergen; Roger L Nation; Jian Li; Jing Zhang; Brian T Tsuji
Journal:  J Antimicrob Chemother       Date:  2017-07-01       Impact factor: 5.790

Review 4.  Vancomycin-Induced Kidney Injury: Animal Models of Toxicodynamics, Mechanisms of Injury, Human Translation, and Potential Strategies for Prevention.

Authors:  Gwendolyn M Pais; Jiajun Liu; Sanja Zepcan; Sean N Avedissian; Nathaniel J Rhodes; Kevin J Downes; Ganesh S Moorthy; Marc H Scheetz
Journal:  Pharmacotherapy       Date:  2020-05-04       Impact factor: 4.705

Review 5.  Fosfomycin: Pharmacological, Clinical and Future Perspectives.

Authors:  Anneke Corinne Dijkmans; Natalia Veneranda Ortiz Zacarías; Jacobus Burggraaf; Johan Willem Mouton; Erik Bert Wilms; Cees van Nieuwkoop; Daniel Johannes Touw; Jasper Stevens; Ingrid Maria Catharina Kamerling
Journal:  Antibiotics (Basel)       Date:  2017-10-31

6.  Cilastatin protects against tacrolimus-induced nephrotoxicity via anti-oxidative and anti-apoptotic properties.

Authors:  Kang Luo; Sun Woo Lim; Jian Jin; Long Jin; Hyo Wook Gil; Dai Sig Im; Hyeon Seok Hwang; Chul Woo Yang
Journal:  BMC Nephrol       Date:  2019-06-14       Impact factor: 2.388

7.  Protective Effects of Cilastatin against Vancomycin-Induced Nephrotoxicity.

Authors:  Blanca Humanes; Juan Carlos Jado; Sonia Camaño; Virginia López-Parra; Ana María Torres; Luís Antonio Álvarez-Sala; Emilia Cercenado; Alberto Tejedor; Alberto Lázaro
Journal:  Biomed Res Int       Date:  2015-10-04       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.